KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Change in Cash: 2009-2024

Historic Change in Cash for Alnylam Pharmaceuticals (ALNY) over the last 16 years, with Dec 2024 value amounting to $153.8 million.

  • Alnylam Pharmaceuticals' Change in Cash rose 187.07% to $376.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $390.3 million, marking a year-over-year increase of 480.05%. This contributed to the annual value of $153.8 million for FY2024, which is 386.50% up from last year.
  • Per Alnylam Pharmaceuticals' latest filing, its Change in Cash stood at $153.8 million for FY2024, which was up 386.50% from -$53.7 million recorded in FY2023.
  • Alnylam Pharmaceuticals' 5-year Change in Cash high stood at $323.1 million for FY2021, and its period low was -$53.7 million during FY2023.
  • Over the past 3 years, Alnylam Pharmaceuticals' median Change in Cash value was $46.4 million (recorded in 2022), while the average stood at $48.8 million.
  • Per our database at Business Quant, Alnylam Pharmaceuticals' Change in Cash surged by 738.78% in 2021 and then slumped by 215.66% in 2023.
  • Yearly analysis of 5 years shows Alnylam Pharmaceuticals' Change in Cash stood at -$50.6 million in 2020, then soared by 738.78% to $323.1 million in 2021, then slumped by 85.64% to $46.4 million in 2022, then crashed by 215.66% to -$53.7 million in 2023, then spiked by 386.50% to $153.8 million in 2024.